Intellia Therapeutics (NTLA) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Intellia Therapeutics (NTLA) over the last 10 years, with Q4 2024 value amounting to $49.7 million.
- Intellia Therapeutics' Accumulated Depreciation & Amortization rose 2466.07% to $49.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $49.7 million, marking a year-over-year increase of 2466.07%. This contributed to the annual value of $49.7 million for FY2024, which is 2466.07% up from last year.
- Latest data reveals that Intellia Therapeutics reported Accumulated Depreciation & Amortization of $49.7 million as of Q4 2024, which was up 2466.07% from $39.9 million recorded in Q4 2023.
- Over the past 5 years, Intellia Therapeutics' Accumulated Depreciation & Amortization peaked at $49.7 million during Q4 2024, and registered a low of $19.3 million during Q4 2020.
- For the 5-year period, Intellia Therapeutics' Accumulated Depreciation & Amortization averaged around $33.6 million, with its median value being $33.2 million (2022).
- In the last 5 years, Intellia Therapeutics' Accumulated Depreciation & Amortization surged by 3939.28% in 2020 and then skyrocketed by 2006.69% in 2023.
- Over the past 5 years, Intellia Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $19.3 million in 2020, then skyrocketed by 35.09% to $26.1 million in 2021, then rose by 27.13% to $33.2 million in 2022, then increased by 20.07% to $39.9 million in 2023, then increased by 24.66% to $49.7 million in 2024.
- Its Accumulated Depreciation & Amortization was $49.7 million in Q4 2024, compared to $39.9 million in Q4 2023 and $33.2 million in Q4 2022.